Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”

PMBI launches Jan Aushadhi Chyawanprash Special

Chyawanprash Special will be available at all Jan Aushadhi Kendras

Biocytogen and Hansoh Pharma announce an antibody license agreement

Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules

Granules partners with Greenko ZeroC to enable green molecule solutions

Greenko ZeroC will supply Carbon Free Energy and enable Green Hydrogen along with its various chemical derivatives.

Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies

Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze

Alembic receives USFDA final approval for Fulvestrant Injection

Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA

NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData

China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.

Searchlight Pharma to acquire Miravo Healthcare

Miravo to remain a Canadian controlled and operated company following closing of the transaction

Lupin receives USFDA approval for Brivaracetam Tablets